Navigation Links
Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort
Date:10/15/2007

NEW YORK, Oct. 15 /PRNewswire/ -- Senex Biotechnology, Inc. presented today new results from its drug discovery program at the 8th International Conference on Alzheimer's Disease Drug Discovery in New York. Dr. Igor Roninson, the President of Senex, described the identification of the first drug candidates that block aging cells from producing excessive amounts of several proteins involved in Alzheimer's disease, including: amyloid precursor protein (APP); BACE1 that converts APP to beta-amyloid; and tissue transglutaminase (TGM2) that cross-links beta-amyloid to form amyloid plaques. Excessive accumulation of beta amyloid and amyloid plaques is believed to cause the symptoms of Alzheimer's disease. The signaling pathway targeted by Senex compounds was also implicated in cancer and some other diseases of old age, providing additional disease targets for drug development.

Because of their unique mechanism of action, Senex drug candidates only inhibit aging-associated increases in Alzheimer's disease-associated proteins, and therefore, may be better tolerated than drug candidates that reduce APP and APP-converting enzyme activities below normal levels.

In a study first reported by Dr. Roninson in 2000 and awarded the first annual Life Extension Prize, human cells that cease dividing were discovered to increase the production of many proteins that promote the development of Alzheimer's disease, cancer and several other diseases associated with old age. Senex scientists have developed and applied a proprietary high-throughput screening assay for compounds that prevent the induction of such proteins in non-dividing cells. The lead class of active compounds identified by Senex inhibits the induction of disease-associated genes and changes the typical "aged" (senescent) appearance of cells that cease dividing. These compounds also increase the activity of tumor-suppressor proteins that prevent the development of cancers. Senex is planning to develop its proprietary compounds as pharmaceutical agents.

Geneticist Richard Davidson, Ph.D., former Head of the Department of Molecular Genetics at the University of Illinois at Chicago and currently Administrative Director of Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, commented, "The relatively recent discovery that aging cells overproduce proteins that cause Alzheimer's and other age-related diseases was one of the most striking findings in the field of functional genomics, made possible by the sequencing of the human genome. It is exciting to see how rapidly a genomics discovery can lead to the development of pharmaceuticals that may potentially help seniors to lead healthier lives."

About Senex Biotechnology

Senex Biotechnology, Inc. is a privately-held drug discovery and development company in Albany, NY, which is developing drugs against cancer and major diseases of old age, by targeting signaling pathways activated in the process of cell senescence (aging).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future the financial performance and clinical and business prospects for Senex products, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the optimization and development of our drug product candidates; manufacturing capabilities or other factors; and other risk factors. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

For more information, contact info@senexbio.com.


'/>"/>
SOURCE Senex Biotechnology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Olympics of biotechnology has international flavor
2. Making Wisconsin the biotechnology leader
3. Let the olympics of biotechnology in the Midwest begin!
4. The mushrooming of biotechnology in the U.S.
5. 42 days until the 2006 Olympics of Biotechnology in Chicago
6. Third coast of biotechnology makes strong showing at VC conference
7. State wants to encourage industrial biotechnology
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. First graduates boon to Wisconsin biotechnology
10. Americas Third Coast nurtures biotechnology
11. Florida: Investing Heavily in Biotechnology - Governor uses state funds to attract large biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent ... patients over profits, while only 16 percent believe health ... released today. Meanwhile, 36 percent of U.S. adults believe ... patients over profits, compared to hospitals (23%). ... maelstrom," said Wendy Salomon , vice president of ...
(Date:1/17/2017)... Hong Kong (PRWEB) , ... January 17, 2017 ... ... management software, and NetDimensions, a global provider of learning and performance management systems ... for the mainland China market. , “In the life sciences industry, organizations must ...
(Date:1/16/2017)... Jan. 16, 2017   Valentin A. Pavlov, PhD ... , president and CEO of The Feinstein Institute ... analysis of how the nervous system regulates the immune ... bioelectronic medicine devices to treat disease and ... Neuroscience . The paper examines various studies ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The biosimilars market is expected to reach USD ... a CAGR of 26.3%. The global biosimilars market ... Factors such as rising incidence of various diseases, increasing demand for ...
Breaking Biology Technology:
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):